(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064788 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number:
PCT/US2004/000955

(22) International Filing Date: 14 January 2004 (14.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/439,950 14 January 2003 (14.01.2003) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/439,950 (CIP)
Filed on 14 January 2003 (14.01.2003)

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES, LTD.** [IL/IL]; 5, Basel Street, P.O. Box 3190, 49131 Petach-Tikva (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COHEN-VERED, Sharon** [IL/IL]; Azar 167, Kfar Saba (IL). **NAFTALI, Esmira** [IL/IL]; 44/6, He-beiyar St., 48056 Rosh Haayin (IL). **WEINSTEIN, Vera** [IL/IL]; Rambam St., P.O. Box 846, 90805 Mevaseret Zion (IL). **GILBERT, Adrian** [IL/IL]; 60B Apt., 5, Hankin Street, 43465 Ra'anana (IL). **KLINGER, Ety** [IL/IL]; 16, Agadati Street, Tel Aviv 39930 (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunahm LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

(57) Abstract: The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH_2-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH; and a substituted 13-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition ha.s a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

WO 2004/064788 A2